Savara Management

Management criteria checks 2/4

Savara's CEO is Matt Pauls, appointed in Sep 2020, has a tenure of 4.17 years. total yearly compensation is $3.76M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth €1.64M. The average tenure of the management team and the board of directors is 3.2 years and 7.6 years respectively.

Key information

Matt Pauls

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage	15.8%
CEO tenure	4.2yrs
CEO ownership	0.3%
Management average tenure	3.2yrs
Board average tenure	7.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Matt Pauls's remuneration changed compared to Savara's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$83m
Jun 30 2024	n/a	n/a	-US$75m
Mar 31 2024	n/a	n/a	-US$64m
Dec 31 2023	US$4m	US$595k	-US$55m
Sep 30 2023	n/a	n/a	-US$49m
Jun 30 2023	n/a	n/a	-US$43m
Mar 31 2023	n/a	n/a	-US$40m
Dec 31 2022	US$2m	US$580k	-US$38m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$39m
Mar 31 2022	n/a	n/a	-US$41m
Dec 31 2021	US$2m	US$560k	-US$43m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$46m
Mar 31 2021	n/a	n/a	-US$44m
Dec 31 2020	US$2m	US$170k	-US$50m
Sep 30 2020	n/a	n/a	-US$68m
Jun 30 2020	n/a	n/a	-US$69m
Mar 31 2020	n/a	n/a	-US$81m
Dec 31 2019	US$64k	n/a	-US$78m
Sep 30 2019	n/a	n/a	-US$57m
Jun 30 2019	n/a	n/a	-US$57m
Mar 31 2019	n/a	n/a	-US$47m
Dec 31 2018	US$114k	n/a	-US$62m
Sep 30 2018	n/a	n/a	-US$58m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$53m
Dec 31 2017	US$75k	n/a	-US$31m

Compensation vs Market: Matt's total compensation ($USD3.76M) is above average for companies of similar size in the German market ($USD1.03M).

Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.

CEO

Matt Pauls (53 yo)

4.2yrs

Tenure

US$3,759,723

Compensation

Mr. Matthew Pauls, J.D. M.B.A. also known as Matt, is Director at NVN Liquidation Inc. He serves as Director of Soleno Therapeutics, Inc. since August 15, 2023 and is its Lead Independent Director aince Au...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Matthew Pauls	Chairman & CEO	4.2yrs	US$3.76m	0.30% € 1.6m
David Lowrance	CFO, Chief Administrative Officer & Secretary	8yrs	US$1.52m	0.048% € 264.1k
Robert Lutz	Chief Operating Officer	1.8yrs	US$2.66m	0% € 0
Kate McCabe	Senior VP & General Counsel	6.7yrs	no data	no data
Anne Erickson	Chief Business Officer	4.1yrs	no data	0.069% € 378.2k
Brian Maurer	Head of Clinical Operations	3.5yrs	no data	no data
Charles LaPree	Senior Vice President of Global Regulatory Affairs & Quality Assurance	3.3yrs	no data	no data
Peter Clarke	Executive Vice President of Global Technical Operations	3.2yrs	no data	no data
Raymond Pratt	Chief Medical Officer	2yrs	US$698.69k	0.064% € 352.9k
Scott Wilhoit	Executive Vice President of Global Commercial	1.8yrs	no data	no data
Brian Robinson	Senior VP of Global Medical Affairs	1.6yrs	no data	no data
Yasmine Wasfi	Executive VP and Head of Clinical Development & Clinical Operations	less than a year	no data	no data

3.2yrs

Average Tenure

56yo

Average Age

Experienced Management: YB4P's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Matthew Pauls	Chairman & CEO	7.6yrs	US$3.76m	0.30% € 1.6m
David Ramsay	Independent Director	7.6yrs	US$158.13k	1.35% € 7.5m
Joseph S. McCracken	Lead Independent Director	11.1yrs	US$155.13k	0.11% € 603.9k
Richard Hawkins	Independent Director	14.1yrs	US$149.13k	0.0074% € 40.8k
Nevan Elam	Independent Director	15.8yrs	US$157.63k	0% € 0
Bruce Trapnell	Member of Clinical Advisory Board	no data	no data	no data
Francesco Bonella	Member of Clinical Advisory Board	no data	no data	no data
Yoshikazu Inoue	Member of Clinical Advisory Board	no data	no data	no data
An van Es-Johansson	Independent Director	4.9yrs	US$155.63k	0% € 0
Cormac McCarthy	Member of Clinical Advisory Board	3.8yrs	no data	no data
Tisha Wang	Member of Clinical advisory Board	1.8yrs	no data	no data

7.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: YB4P's board of directors are considered experienced (7.6 years average tenure).

Savara Management

Management criteria checks 2/4

Key information

Recent management updates

Savara Appoints Braden Parker as Chief Commercial Officer

Savara Inc., Annual General Meeting, Jun 06, 2024

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection

Chairman & CEO recently sold €357k worth of stock

Independent Director recently bought €242k worth of stock

Savara Inc. Announces New Leadership Appointments

Recent updates

New minor risk - Profitability

New minor risk - Share price stability

New minor risk - Profitability

Savara Appoints Braden Parker as Chief Commercial Officer

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

New minor risk - Profitability

Savara Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Savara Inc., Annual General Meeting, Jun 06, 2024

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024

No longer forecast to breakeven

New minor risk - Profitability

Chairman & CEO recently sold €357k worth of stock

Forecast to breakeven in 2026

Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis

No longer forecast to breakeven

New minor risk - Profitability

No longer forecast to breakeven

No longer forecast to breakeven

New minor risk - Shareholder dilution

Savara Inc. has completed a Follow-on Equity Offering in the amount of $79.994334 million.

Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis

Independent Director recently bought €242k worth of stock

No longer forecast to breakeven

Savara Inc. Announces New Leadership Appointments

Savara Inc. Announces New Leadership Appointments

Independent Director recently bought €52k worth of stock

Forecast to breakeven in 2025

Independent Director recently bought €77k worth of stock

Independent Director recently bought €67k worth of stock

Independent Director recently bought €195k worth of stock

Independent Director recently bought €143k worth of stock

Savara Announces Resignation of Badrul Chowdhury as Chief Medical Officer, Effective on September 9, 2022

Independent Director recently bought €131k worth of stock

Savara Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Savara Inc., Annual General Meeting, Jun 02, 2022

Independent Director recently bought €57k worth of stock

Independent Director recently bought €191k worth of stock

Independent Director recently bought €152k worth of stock

Independent Director recently bought €98k worth of stock

Savara Inc. Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Savara Inc.(NasdaqGS:SVRA) dropped from Russell 3000E Value Index

Independent Director recently bought €66k worth of stock

Savara Inc. has completed a Follow-on Equity Offering in the amount of $113.011275 million.

Revenue beats expectations

New 90-day high: €1.68

New 90-day high: €1.34

Savara Inc. Provides Update on Molgradex in aPAP and the Phase 3 IMPALA 2 Trial

Savara Inc. Announces CEO Change

New 90-day high: €1.18

New 90-day low: €0.86

New 90-day low: €0.89

New 90-day low: €0.96

Savara Inc. Announces Management Changes

New 90-day low - €1.01

New 90-day low - €1.53

Savara Inc.(NasdaqGS:SVRA) dropped from Russell 3000 Growth Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age